BioDrugs

, Volume 26, Issue 2, pp 125–130

Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria

  • Gillian M. Keating
  • Katherine A. Lyseng-Williamson
  • Kate McKeage
Adis Drug Clinical Q&A

DOI: 10.2165/11208420-000000000-00000

Cite this article as:
Keating, G.M., Lyseng-Williamson, K.A. & McKeage, K. BioDrugs (2012) 26: 125. doi:10.2165/11208420-000000000-00000
  • 108 Downloads

Abstract

The targeted terminal complement inhibitor eculizumab (Soliris®) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Gillian M. Keating
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  • Kate McKeage
    • 1
  1. 1.AdisMairangi Bay, North Shore, AucklandNew Zealand

Personalised recommendations